The Trump administration wants American biotech companies to play hardball with foreign health systems — and stop giving special discounts that aren’t offered here at home.

To that end, the White House is moving to finalize two Medicare pilot programs, “GLOBE” and “GUARD.” Both would require biotech firms to send rebates to the federal government, determined by the difference between the foreign prices of their drugs and the prices that Medicare pays.